ストックスクリーナーアプリを入手
5.50
0.00%
0.00
アフターアワーズ：
5.40
-0.10
-1.82%
Passage Bio Inc (PASG) 最新ニュース
Layoff Tracker: Genentech R&D cuts include longtime top exec - BioSpace
Passage Bio Inc. (PASG) Surges Over 9% as Biotech Stock Tests Key ResistanceEarnings Quality Factor - newsline.com
Fierce Biotech Layoff Tracker 2026: Genentech trims R&D; Neumora cuts 35% - Fierce Biotech
Guggenheim Downgrades Passage Bio(PASG.US) to Hold Rating - Moomoo
Passage Bio (PASG) Downgraded to Neutral as Strategic Review Ini - GuruFocus
Passage Bio (PASG) Slides 6.33% as Stock Approaches Key Support at $5.34SuperTrend - newsline.com
Thryv Holdings Faces Continued Pressure as Shares Slide to $3.72Dollar Neutral Pair - newsline.com
Passage Bio Inc. (PASG) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentGAAP Earnings Report - newsline.com
PASG Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SentimentAnalyst Consensus Shift - newsline.com
Passage Bio Inc. (PASG) Edges Higher as Buyers Defend Key Support LevelCumulative Volume - The Legal Advocate
Delhi Airport Becomes First Indian Infrastructure Facility to Deploy 'Skycast' Aviation Weather Intelligence SystemGAAP Earnings Report - newsline.com
Unusual Machines (UMAC) Surges 57% as Momentum Builds Above Key SupportInstitutional Sentiment - The Legal Advocate
Passage Bio Ends Gemma Collaboration, Philadelphia Office Lease - Moomoo
Passage Bio Ends Key Collaborations and Office Lease - TipRanks
Passage Bioterminates research, collaboration and license agreement with Gemma Bio Therapeutics - marketscreener.com
Passage BIOTerminates Research, Collaboration And License Agreement With Gemma BIO Therapeutics - TradingView
Passage Bio (NASDAQ: PASG) ends Gemma deal, pays $2.3M to exit lease - Stock Titan
Passage Bio Inc. (PASG) Q1 2026 Earnings: Narrower-Than-Expected Loss Fuels Share GainsOne-Time Gain Impact - newsline.com
PASG Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ReactionUpward Estimate Revision - The Legal Advocate
PASG Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Market ResponseEarnings Volatility Report - The Legal Advocate
Passage Bio, Inc. 2026 Annual Meeting Results: Stockholder Votes and Key Corporate Information (Form 8-K) - Minichart
Passage Bio Shareholders Approve Directors and Executive Pay - TipRanks
Passage Bio (NASDAQ: PASG) holders choose annual say-on-pay at 2026 meeting - Stock Titan
PASG Technical Analysis & Stock Price Forecast - Intellectia AI
Barnes & Noble Education Inc (BNED) Surges 6.36%: Key Levels to WatchWMA Signal - newsline.com
PASG Q1 2026 Earnings: Narrower-than-expected loss lifts sharesAnalyst Consensus Shift - thelegaladvocate.com
Passage Bio Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentCEO Earnings Statement - The Legal Advocate
PASG Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Operational ProgressCrowd Sentiment Entry - Newser
Passage Bio Inc. (PASG) Holds Steady Near Support as Biotechnology Sector Faces HeadwindsBeta Neutral Pair - Newser
Director Sondhi Dolan receives 10,539 Passage BIO (PASG) stock options - Stock Titan
Passage BIO (NASDAQ: PASG) director Derrell Porter receives grant of 10,539 stock options - Stock Titan
Passage BIO, Inc. (PASG) director gets 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) director Sandip Kapadia awarded 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) director receives 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) awards 10,539 options to director at $5.08 - Stock Titan
Passage Bio Inc stock (US70267E1055): gene therapy developer back in focus after recent moves - AD HOC NEWS
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside? - Insider Monkey
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Passage Bio Inc stock (US70267E1055): gene therapy hopes meet analyst caution - AD HOC NEWS
Gene Therapy In CNS Disorder Therapeutics Market Size in the 7MM - openPR.com
Passage Bio stock (US70267E1055): Cuts 75% of workforce after FDA feedback - AD HOC NEWS
Passage Bio, Inc.Common Stock (NQ: PASG - FinancialContent
TradingKey - TradingKey
Indian Stock Market Rises: Sensex Gains 50 Points, Nifty 50 Holds Above 23,400Slow Growth Warning - newsline.com
Krabbe Disease Treatment Market to Reach USD 786.45 Million - openPR.com
TD Cowen Downgrades Passage Bio(PASG.US) to Hold Rating - Moomoo
MSN Money - MSN
GM1 Gangliosidosis Treatment Market to Reach USD 626.86 Million - openPR.com
Passage BIO, Inc. 1Q 2026: Net loss $(7.6)M, EPS $(2.36) — 10-Q Summary - TradingView
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Passage Bio (NASDAQ: PASG) faces cash shortfall, cuts workforce 75% - Stock Titan
CCORF Maintains Passage Bio(PASG.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Why Passage Bio (PASG) business model holds up in any market (Smart Money Active) 2026-05-11Social Flow Trades - newser.com
A Quick Look at Today's Ratings for Passage Bio(PASG.US), With a Forecast Between $21 to $32 - Moomoo
Number of shareholders of Passage Bio, Inc. – BOATS:PASG - TradingView
A Quick Look at Today's Ratings for Passage Bio(PASG.US), With a Forecast Between $8 to $23 - Moomoo
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):